Faculty
Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts
Michael E. Wechsler, MD, MMSc
Professor, Department of Medicine
Co-Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health
Denver, Colorado
Target Audience
This activity is intended for allergists/clinical immunologists, pulmonologists, pediatricians, and other specialist clinicians involved in the management of pediatric patients with asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Assess pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
- Describe the clinical profiles and evidence for biologic treatment options for pediatric asthma
- Coordinate the multimodal care of pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making
Program Description
Overall, the web-based curriculum is designed to provide learners with actionable recommendations on the latest evidence and expert opinion related to managing pediatric patients with moderate-to-severe asthma. Focused online education delivered in three 30-minute modules fits well with the time-limited schedules of clinicians, while varied content formats cater to different learning styles.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COIs) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Wanda Phipatanakul, MD, MS: Consultant: Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals
Michael E. Wechsler, MD, MMSc: Consultant: AstraZeneca plc, Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Planners and Managers
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 70% on the posttest, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.
Jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
